0001104659-25-059362.txt : 20250613 0001104659-25-059362.hdr.sgml : 20250613 20250613161523 ACCESSION NUMBER: 0001104659-25-059362 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250612 ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 FILED AS OF DATE: 20250613 DATE AS OF CHANGE: 20250613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Transcode Therapeutics, Inc. CENTRAL INDEX KEY: 0001829635 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 811065054 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40363 FILM NUMBER: 251046760 BUSINESS ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-301-6857 MAIL ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 8-K 1 tm2517990d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2025

TRANSCODE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40363		81-1065054
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

TransCode Therapeutics, Inc.

6 Liberty Square, #2382
Boston, Massachusetts 02109

(Address of principal executive offices, including zip code)

(857) 837-3099

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		RNAZ		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.08 Shareholder Director Nominations

TransCode Therapeutics, Inc. (the “Company”) intends to hold its 2025 annual meeting of stockholders (the “2025 Annual Meeting”) on August 29, 2025. The Company has set the close of business on July 11, 2025, as the record date for the determination of stockholders who are entitled to notice of, and to vote at, the 2025 Annual Meeting and any adjournments thereof. The time and location of the 2025 Annual Meeting shall be specified in the Company’s definitive proxy statement on Schedule 14A for the 2025 Annual Meeting.

The Company’s 2024 annual meeting of stockholders (the “2024 Annual Meeting”) was held on June 13, 2024. As the date of the 2025 Annual Meeting will have been changed by more than 30 days from the one-year anniversary of the 2024 Annual Meeting, the Company is informing stockholders of this change in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is informing stockholders of the new dates described below for submitting stockholder proposals and other matters.

Pursuant to Rule 14a-8 of the Exchange Act, a stockholder intending to present a proposal to be included in the proxy statement for the 2025 Annual Meeting must deliver the proposal in writing to the Company’s Secretary at its corporate office for which the address is 6 Liberty Square, #2382, Boston, MA 02109, no later than a reasonable time before the Company begins to print and mail the proxy materials for the 2025 Annual Meeting. To be considered for inclusion in this year’s proxy materials for the 2025 Annual Meeting, shareholder proposals must be submitted in writing on or before the close of business on June 23, 2025, which the Company believes to be a reasonable deadline under the applicable rules of the Exchange Act. In addition to complying with such deadline, stockholder proposals intended to be considered for inclusion in the Company’s proxy materials for the 2025 Annual Meeting must also comply with Delaware law as well as all applicable rules and regulations promulgated by the U.S. Securities and Exchange Commission (the “SEC”) under the Exchange Act. Any director nominations and stockholder proposals received after such deadline will be considered untimely, will not be considered for inclusion in the proxy materials for the 2025 Annual Meeting, nor will they be considered at the 2025 Annual Meeting.

In addition, any stockholder who wishes to make a nomination or introduce an item of business at the 2025 Annual Meeting, other than pursuant to Rule 14a-8 under the Exchange Act, must deliver proper notice in writing to the Company’s Corporate Secretary at our corporate address at 6 Liberty Square, #2382, Boston, MA 02109, not later than the close of business on June 23, 2025.

In addition, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice in writing to the Company’s Corporate Secretary at our corporate address at 6 Liberty Square, #2382, Boston, MA 02109, setting forth the information required by Rule 14a-19 under the Exchange Act no later than the close of business on June 23, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		TransCode Therapeutics, Inc.

Date: June 13, 2025	By:	/s/ Thomas A. Fitzgerald
		Thomas A. Fitzgerald
		Interim Chief Executive Officer; Chief Financial Officer

EX-101.SCH 2 rnaz-20250612.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 rnaz-20250612_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 rnaz-20250612_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 12, 2025
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 12, 2025
Entity File Number	001-40363
Entity Registrant Name	TRANSCODE THERAPEUTICS, INC.
Entity Central Index Key	0001829635
Entity Tax Identification Number	81-1065054
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6 Liberty Square
Entity Address, Address Line Two	#2382
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	857
Local Phone Number	837-3099
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RNAZ
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://transcodetherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports rnaz-20250612.xsd rnaz-20250612_lab.xml rnaz-20250612_pre.xml tm2517990d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2517990d1_8k.htm": { "nsprefix": "rnaz", "nsuri": "http://transcodetherapeutics.com/20250612", "dts": { "schema": { "local": [ "rnaz-20250612.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rnaz-20250612_lab.xml" ] }, "presentationLink": { "local": [ "rnaz-20250612_pre.xml" ] }, "inline": { "local": [ "tm2517990d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://transcodetherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-06-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2517990d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-06-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2517990d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001104659-25-059362-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-25-059362-xbrl.zip M4$L#!!0 ( .N!S5J%(:P<,P, D, 1 BTR,#(U,#8Q,BYX MOZ93+)!2P<.[6=0OOK M9^>-EP #MN63Y^Y\=T[:Y[.(HE<0DG#6L3RG9B%@/@\(&W6LAX%],>C> MW%CH_.SC!Z2?]B?;1M<$:-!"5]RW;UC(3]$W'$$+?04& BLN3M$CIHFQ\&M" M0: NCV(*"O1&YJF%FDYMB&Q[!]E'8 $7#_V;4G:L5"Q;KCN=3AW&7_&4BXET M?![M)CA06"6R5*O-:OFS&_V62+\D'^&+X^GG69\\C8!]27JX\>S_P"^W+\.[ MX/VY?Q3]G,Q4=/D^'$QP^'9!ZO?-^E%7#!Z2YV@R&%UF+MO2'T.$D:X%DQW+ MY)>G-VTX7(S<>JWFN4^WO4&*LS)@:T8)FZR#>R%S$+/V@[^#-+MAERFR[J^"J4B(AN&-GZ3H6(#4] MS:^G#3D_AVSG^ICZ"3V(.H]O&S.W%Z=:.>YBWOH0HG1.6Z:C.I8DYJ*TA$&?K]@AMD_$@+N?\PTNCYE^7QW%MDZ7"X58 M9<"W7;;99Z+'_51J"\6\V07/-B;;J]L-SYG)8![I/D',3V"_( K> 4%LN/+7 M^9>;X&9A6JBQJ],-GXZM3M=R7*!*%I:#0UC\T/Q%#*G,7D$LE3-0PC421K1N MZSHVO,WA_(F9OLN#FL#G"5/B;9]&6*04+X=58_Z+L%LA"GQ6!//7<*C; [J@ MZGQ="[3=3$TO?P-02P,$% @ ZX'-6B0NS8S\"@ ?X8 !4 !R;F%Z M+3(P,C4P-C$R7VQA8BYX;6S-G5UOXS86AN\7V/_ >F]V@7&<.$"!I#,M,IZD M,)HF:>R9[FZQ*&B)<8309$#)B?WOEY1$6:)X)"6+)3D7,Q[Q/=1+\3%)?1U_ M_&FWH>B%B#3A[-/HY.AXA B+>)RP]:?1U\7X8C&;ST6,?!HQ/OKI MQ[_^!I_8RT;JTWCD^GX].1H ME\8C??#S(R@X)??D >7-/,_VSY*D-%$@C,IMCX(\V,U0(28J?L+(&FFYVQ,B\-8A#\(OK'NMFPUMQ3^25=5?'%8Y"X HPV9("G? MBHB\J5?J;J&C5#K:4*E0*RK"QE\7HQ]S#?I#J_[S<7*HQ4%'RR70=D-8MI0U M6EK0+';5S393NI?K94%TLL60V<=:@I3&<0=?R!W':N=7%*\M]HUR5UULM:7[ MN%$81"?;')F]7&F0$OGJYB\DC43RK);S7>UHR)QWNL5DJ^]KFK 0:!N#2:AI M/0WL]V2=J*E%65#GMT1M[!C& +WKH;_3MCD76,5!0#/$(3A;U(-0%>6)HPO& MMIC>DVR$P>@&5/L$XRI)(TP++U=R6]K1/(O6 M-2"@71.2EC H4"!W("Q%@&8F#_$*S+\(%L-PJ2G]P-*R:D>ED@4(BNFM#Q.E M]P+);"M$PS4\X\!29S=E>\Q6]V>UW<)6*8>8@2;8\K<$F W MV:2@J0F(!*LQ@(:#-G^FU L1,SDR"4SG+":[7\@>;%=+YY8)P&83"D,4$!5V M9P 6I1CE:B3E7L"X$\D&B_TBB7JFBK;0+1J0T28;IBH@. !K !VE&BWF,Y\S MR1+OYK$$-7E(BN?!>R@!]6YAZ;'=9 80!X1.MT. (!F$FE$^09JSB(MG7GO< M8<:W<@#05(U>"% MN(LXE@^H?F="@TIT%#<_HN:&3'>QUK9O+C MK5CR5]O#V:#2"S)MJU9@#K+P<&EYZX-%!:CUC KQB4F^L+H5=X*_)"R"E\R0 MW LP@&DK-88V/'3L!OOXJ1;$.L[K6%,LRGN_)%KF9Y1IFK0/,84F/$B:QGH' MET+M$XD[GF:8_CMY[CP1MXN]X&$U;(6DH0P/%9N]/F"*&"2#?)Q8E[BJ&QK6 M5\F,O %ML'5X!KA4& 8'-4?L5X.+J22%RWU MLC"ZN&VHUO?(&?R 0%OBJJAPP9?9Z+D.Y MSM/5>)5A(K4/W[4R9S.[::>:R'5!$+UKNFE-T[K<<6_^+I),[GG&-YLM*^_R MV)X;!'2N>KG3INYQJRB(WN]R9I)0:E%3[!B+!:=)E&0)6_\J3SY%@FVMLHE< M 0$;U#2T%4&@ -HR.3@(D58ZAN!.$ 4AD1V1OP2H$@N)VX<'ZVS?)78%1;]A M#0>L# *27GLF+#)@'-4B4!&"\AB_V,S3=$O$F^"QA'A""#0/@-32AX@39+(7 MJB+0)UL+$FWE_+@_F:Z6249M)Y=MB;,Y"3!7S4A&>1!L *9,%O(RQ!_0R?3O MJW\@'>6X^V_X4F"5.W:QWZPX!;)/656N(.BPJ#FP2() ?9ETG##42E%A=9' M=JJ&64MSC')7 %AMZ:YO% ;1Z39'K2]_HZ\]#?F7N^A1FB+ "PEVF>NAWV;2 M'/[KFB 0Z##6.BDII4AK?;R0<)BRUOV+@+6W1<"Z9Q&P#G$1L!ZZ"%A[6P3H MW18I0N2X=+NBR1H#R0D[U:ZAZ+!L\F&1!H4*[ \<,ZH0=(AQG=$R3W&FTO.+ M3;[_*_G!TDI YRRG99?-*JFE310$(UW.6FDMBZ1S-3%2:M=<;.,D(W%AYBIA MF$4)IE5Z1-L5\?X09[0,-%^!TZ,/@Z%A)ELX%6$ZEV$5>$AUZ?I2>O$ QN^$ MTE\8?V4+@E/.2%Q<2['=*>K6NWUBIL=V\Z$90!P$3D,< H_.J*#QDXI".JR\ M$N:%I&^<;EF&1?XNN;"-3(#.+3F S28QAB@@4NS. $(J,2K4?E[0+K)'5(NL MXG>'P 9"O:W>:-M[:MFH#8J;3(/0.=YGSX[ V+J(\O6*9$?5[$<=3XH;* M?>*8EL5V[IA*$A >-E\=&60$TEHO+"PVF-+/VS1A)(4G(D/EE@6KQ28+#4E M+-A\ 2SD4J2U7EBXW!"QEM/;SX*_9H]E?E:P;8#:+1N=EIN,6*4!L=+E#V!& MAZ B1J?4]0//[I!0O,BR"+?4(G6,#6C68*:E"PD8R%R+%DHB=;WEAF=HR='7 ME*#LD:#+\F?HZIG@BWI\_=)(%*D7(HI5.8NQL"'4)7;^JR.@X=9OC[2408#4 M:P_^'9(J ND0Q]3<2H9%_3PN-S'/R 9\VZ$_Q!5!0\UKCOKT0= TT*3)5![6 M/+G. Y&*])G-J)[<'E[B-42.5\86@\;"N*8(@A'0%K0LKO]6@)_<>=L53:(K MRC%\E:6A<9PQKVW/2)9W$ 1$0-L5E"(O%Z)3+7&Q@$A&]U M"YWJI:A> 5JI9\3**M ?JA*4UV+[_?+ZIFOY26[6F^1?*YP2N>6_4$L#!!0 M ( .N!S5K9H,BTR,#(U,#8Q,E]P&UL MS9Q-<]LV$(;OG>E_8-6S+$MJT]JQFW$4*Z.)$[N6D[2]9" 2DC & 0T 6E)_ M?0%25/1!@.L>N/;!EJD%L.^S(,@E %Z\6:4\>J)*,RDN6]V3TU9$12P3)F:7 MK<_C]M5X,!JU(FV(2 B7@EZVA&R]^>/''R+[<_%3NQT-&>7)>?1.QNV1F,K7 MT2>2TO/H/154$2/5Z^@+X9D[(H>,4Q4-9+K@U%#[1='P>?3JY'02M=N :K]0 MD4CU^7ZTK79NS$*?=SK+Y?)$R">RE.I1G\0RA54X-L1D>EO;Z>IT\U,4O^!, M/)Z[7Q.B:61Q"7V^TNRRY=K=-+OLGT@UZ_1.3[N=OS[>C.,Y34F;"8^U^]V2EDU8)/R>H)*?W=!JYOS9ZVU:-(D+;#D?-W':7 M!MI0@_]JF>K^>ONKV7$,_[QF9]<)V4LU< M'VM%G3TG%HIJ*DRN^\8>V"M"5\;V+9J4%;GV_Y>;AAE7XBXT\T%WV\SP"FL8G,_G422BSD>CUW0<'I9\#L?]\RQNZ MFFCK>6S*FCB94)[7_\W:')AT&O"J)/%@:ZQV:M_BT*?="%ZI.)(JHQ0B\7YP]VO,\8$ /[8&$G^%>N/AT8B$?#RGG+O"_T@M4@3NJ&(RL9=T!6!_9 RD M?H9)W:,0E?>U2*"TMZ;@_ "HXK>&(D=)0.M$-LS\6AAFUFXRX%.6 M3KX_.-UG?6P%98R2=/I$H; MGS0(XR8Y0GP/+:&,47+-D#@4S@.K1Q$^$@E= M?:#K$.@C4RAIE!PS* \%]9UB*5'K,8OK!XUC6RALE,PR+!"%]@-9C1*KBDU9 M,4U8#]U;!,H>):T$R44)P4C$4BWDSN/B@R"0XI-<4A(8#)=]\AG24 MH%PEB<6E-W]NF*#=4"@JS<%S1'@!",A\(=A[S\/>@V-'R4-K9;X0[/WG8>_# ML:/DHK4R,;$/[,=;]2"7GAEHKS$4.4HN6B,1$WA^I;E5=TH^L6*U5!WUHQ)0 M](@I:E@L:HKN)*OMH0T*8? M,!9Q=P\M?$N)#DR@?%%RU4HY32-U$5:4^+OOO@44*$H"6B6F89XWTLU]S*4( M/H\]MH)R1C"0:9J)S3,: MSZR8QQ2*%R7]"\IK&/587UC#A.\4=9&F M]K8[7\?EMAVHV^G4-_*&[*'$47*]>J&XY$=:9U0]EW]%*6@44-(^J.BFQQD: M9W;86W=[DP>W8\8SRAQ905FCI'P^40VS_20?%'&;^,;K="*Y?WM(I2&4,$J" M%Y#6,.0]/ZKQ'IA P:)D=I5RD,:$ZU4\)V)&_:L7JBVA@%$RO9 XM+%W!AI[ M9\\<>U$R/I\H)+;%VG![1MU..)L1_TZR8 'P/AM,X@&I3>_?R[?\N/W=*LW] M&-H/U=@]IE#@.%LD0_*:1ITES-"D<&G(!!&Q3:FV^]H\V7E]*6@ 'W%H%& 7$.L48N2@B^2)Y92BI?"*H\YX#' M%(H<<>[0(P]G[66QJ'E[[2E>Y!$B[BL!!8\XB1@6B[0^S5#G,WNB[X@A&P]# M_'TEH/P1)Q3#8M'6SZN!O?#,9'C._, 02AMQ*6RE-!3(XY1P_C;33% ='%L. M#*&0$=>\5DI#@7R=4C6S@]I[)9=FOMG;&8+M*0"%CKBR-2@5!_[J^S[R8O]; MD'R%-?CM!(C8O2*Q7KL1QVXA17$E%PE1'NHA>RAWU(V5?J$-D[]U;^[:O7_* MG1G9O"VTZ*&^%#0**.DJ5#3.M75G)W_PTKIG!^6-F)A6"&90O8A9:(0L%[ULB'E6V,/'Z3LF84C=]HK=G&R A E8 #0EB?OHL%#B/ M"V2:NLU$,GXW-M\8W[Y=[.:H_\ M!U!+ P04 " #K@T]:UOB2+/?^15]V+/OZO/(+5P4+[P/(CHXWA9PQIDO/DW20#0D,9T( M^.M/57<""22*BG/9L[,[XR3=75U=7?>NSNS_=S(RR"-SN&Z9!W\5LOF_"#-5 M2]/-P<%?]4ZCU?KKO[74_M"%;M#5Y ?IH>O:N[G<>#S.CHM9RQGD"M5J-3?! M/FG9:7<2VT_)YPNYF_.SCCID(YK13>Y24V6S089NWB?#Q]99UYYCZ)&N^":8 MI)A; @VMVGQ N',E)QLC7=W8KF79U0VZZMPJ*87MY_"0/68#)DE]"X@SK)#= M'+;/YMW=^/[SKCG7H2;O6\Z(NK"%"*FGP1SDZF M6 C@+&U.=*78W*-\1G&-+9 [F!,:8(12##IZ/#.@U)YU[E/>$V#]AL7.CF4P M'MM;M$2ZJY9GNLXT'A&_,3* .^XR:'@9Z>28]&G62] -!(:Y0^90FWFNKO*L M:HUP2#E?*2AIE!]&M5J*X*]]5W<-5MO/R9^I_1%S*4%H&?;@Z8\'Z89ENLQT M,]VI#>14Y=-!VF43-R>$+ >CX58(X0 MDRL?5'$)H238/4N;$NY.#7:0[@,#[I)"WG9)5Q]!CPLV)FUK1,TM^6(+YG?T M/O*YIC\&PS2=VP:=[A+3,AFVZ9-=Y%GF@""(!UW3F(E2@4_0Z\(; 1Q5/OT B35@TS,7TW0@CI&N"$_9S$<8^H MRVIS[ ,X\[;%4< J"6."E@64PK,'[WSR14CJF;JD)PC7(A%'C'+/835?"'>A M2P J:(K 1UCQP*4\)\'W%R_ZO'&"N=)8G 0D'#9NB: X4C [=2UGWOKJM2^B M%P,S-.,1,ZV1;KXPYXOT6)PT!FS0'%[^(AE]T9M+FA1Y7^?MYV!L+95*[=N! MBAQ19Z";NR2?KOWGCT(EO[>?LVL)'?RFD-)O>P;+7-&!L'=AS3O6-7>(&CO_ M9SK2T+,<0"7C6O8N.32H>D\44.K<,G1MC_B-/*6"@F$.@._5 MKB]:W>81Z73KW68'-JQ76T1GW3-VFHWK=JO;@NGJ%T>D>=/X5+\X:9+&Y?EY MJ]-I75X\A\:+5GA5-+Y2/H0@S[5@_%&VD25*OERJ?OC,\5N^;AH?7[;/R3ZW MJ2FT&;I"U7Q1^'J9S)&E>N@GH'M]J\[\T+E'^C2]O#.G^WFQ==TFY>7;:[/X2?KSR'>]1TB6O! M0!6#6%(H$LLAA?*&MOE#<+#Z!((CG-YS=%<'@,V).J0F*,&ZZA)H+E2+I8]' MY<=L,KI)N*8VLRW')1O!,Z-@%!EW"7N$SL01S4S;W"5+(EE9$,DKX64UI0L6 M+YMVX9M::C_2J^/^JV13IC8.TOK$W=4 ^@CZ#C4ZG0*ZS(S*;B$?)[L1Y-*U M4\]DI*!L$9SEEQ3G-:G3A3TK^WLF8Z V&^@<4P,NAI_Q6Z9X1ONBHXT>AJI@ MG#=JU$)A.02+3I^N==OUBT[C\JB9ZGYJMNM7S>MNJ]'9(JV+1G9YCWKS??I8 M4=EH3F 1 GN4$&>&-:&<<)NI& 9I1 P8#! T# MEJ]BKC<-+(_/-M6TX/G54X8HO*GY*<%#FU&.+1EJI8#*DCD-3LNR&Y#)OX:EI; L"#2]Y_1%\D;L,T*H]^Z7?7(=AWK!@/\>\R)WYM.\_*T>_9T\?UZ M/7L3(7UQF?1S?#"'4/[4?AI5M M>WO]5(])K24@!ZYS(5/(5\H0J[RT!_"'DZ1IXH@70V6INX6\H2-I8>:;W(%O MQS5=>)C[/2LT4CG/((D\C*1E/SI^+6R M[6PG2YHCV["FS)DC&=UWNYCD/<4M0PZ2F9/\[#'(E>0# M+RDL&7TZTHWI[DOH+$M1K];%HQ94[:ENZ*P%O!A3S:[%:WEQB;:[O$B!W()* MJ4942EW3',:Y_^-,-UDA7IT8K4O]^[19T9^,=WF$Y67-$8-#NE9)G>G ].Z4 M=!Z\6$,Y)VJOMK44IR@O+%.)7Z;[Q1P?51HN][;?KATKJZQ12=?^4(H[RC-* MD4@16US:4=S2&O#72Z=KCO_?VX=7;SI=5N?J"7MY.X] 4W #NHV-0B;,!6T^"/&?V#;$!-H,CP,MLB3;A,\ M6=]<4NZ_>8IH(\G71_&N.XPF,V#W<*=TWSCY]OGF=7F>,*,ID3Q.>$YP),O; MSS%6K[:YI"H#63JSP*&Y&EKFLX'*E\.SP>/7B7[7+;Y] 9&4Q^*\L(CB=J:8 MKWZ,B*R<&WI.&.8)FO_\L:,4MO=XRF4&LW$5Q!3+"$L"V&::( J_M2!<6"ZI MV[8!7BUXKC\B%[UQ#.8(PI4+D7-RB/_H*R>@>9\T1&I:(QTT,ZDSRET_E[O. MS-,/I_J=QR%\F*9KC2%3[T5"GMI@AD$78QS7LR:DQPQKC!3 1B2,1&6(H^$KX:^. M[L(&89CKF7ZPR.,U>JG8T.TKT &) 6/"\?>=L30LRR#45-4 M(2WH]$A^+W89<@MW]A+5>BCX?D$'^_ ![_ $Q Z=EN%)O629DE+V>77A& M/ MKS8*V[)7X[A-E&(^"[TW_3J(.5JSK$L0H__+S\_S<\'GYXX%Q@&H;0[.04V! MKC+BF7G[<=#02X5OM+WS*S!S)&.ZO(8U_ M.7GV'ZI17]?-8OLDQI0WT+Z_LC?RSKOQ]6MP=KKS9V)(W<4+.[+"21T2 MU:"<)YZ%S4YVGX]_8T:NB*B2?P91AXIL"I^.>I:QP9,/^SX?H>>&7PPAR MLD!^@8_'0QW>S(\$YVP?=[K[*KV^2H73=N"22\&;%I2>V/JDTP*G^JG2'1T> M]N*U^1L. -^:+HR<%2VBGZZA9K=,09*.:ZGW6\2F#GFDAL?(_^:SF)HG-M[E M&+YP1K;:Z>^S_+/*1@1G4SX_=P0[Q^]"WKW\/ZR-B@MNY"!'M.G7OF)M:NK*?2X0/O$D3CSD=?3!T8\M;D&&;_BZEHKLDT?.1 M3*CNEB>\ 8 3,;XAAR><_94^'4^KG9OOUR\%2.^-AUS'6PR'8@ZG8U%/UR:) M0= OLODB5)'W*7%+Q%S&%"14@GGDGYNF4.=?JS6CP MP9WH,9 0PM 7&X1DK,1,B%J^<,;RER;NY+L6\*#UKL"?@P;9< M-B+E;'Z'B.O=0\O !-J1[H"Z!(U[(>\]8_[MXVZ??!#!9E6S9+EJEFR@YL<2 M%"6_UPA<%W@J[&VFY$D_1ZN!], [..)2%Y@BTP.C [&%.'8"^\$Q;)9$XQ&8 MHG]=]C^7_0/XF-&H>P- DRA5>5TLBR@2'P]A.CES4PA.-2PNDB(]CX/KRSF. M/O6,*2D4Y-@M=(RE\55!Z@A>9A-V%-]I#+S/8 N7$!X/+:RP(>+["H8L;0!; MK:LX(\ U\4WJT0* U-T2 &/6)?H)!UV[LSS'Q-RMP,AA5E^NS(7-$]T,2XT4 M1<2!XT-J&*3'(A>A!#%"&X650S(X8IL"O2FD8)11* M]1E!8B;\=7SSE;@ZA@ZPJ-(+S)E:8,Y2$G..@9N&H-,DG^&5QJ+@LU*6U"6? M:?Z]SJ3]&^NP?4,*F])C6&G@5Q6!PS@"?0P;"4Y5,0]@IIST'6LD %DFR^#5 M2UR&CM\?H\XT-,DBNI(9 X$1U3GH$ GV"7-X* Y##P_B1O08'0V_!982[F5; M<@C-E#?ZF_'5#G&!GY Z.I)^;)BVX25%' ,0>SY[\785PO'.V)3=N*<="!G*DP" MJ:^1,##4=AA'!4!GE,&W/>87%(6Q6FR(@_9I4*BUQ2VB"CJWR*R M GZ+G->)*(G>2ID6,; *@@CQHF ,*+=,<3 CE*]TAB)2TX-@S>229CI2#/AG M1'4C1)V@L((_JS])5Q 8HA4.89?#M!3V%O3&2C9)<%@.RO>,+*^88$LFH)<8 M7NP*V@DI&7)K@]VPS!1 #"T[P9*"AE.*@26=[\*<2(;.'AGWF2A"6(U1#;^7 M%](:=%;321S@851 J:48$SP0W&49^ +X!# 'LK0=C#U8@1VI,8VB\Q M9>H5U)=DADX!HA++X(XIL-T8=>&8@=9'G8@_%JF K.6P@6<$1[F@]CUC --K MJ9ZLF[S&VU\AI8M#9E2;7UZ+Z-I.LS&S6_$GOV"T8!.UP)TUY^ZLF"!$V]2< MMM"9@:2#4]-'B8KLA[1N48IC F+$C.F6;,1LQPI;DK %J5@!,%%%('#H,5V M#FKE'^'9A*1B2_B38#!D#U83?_]QNSB1I63<."D3JMDXMZ][K=_.6SQ>[7$9S[;PHV2[D0Q>>?6/R03%>G^N MD_J'T]WGJIH6;%%OT1:]\,VVL\2O+ MRV]*@!::27U$&D.=]<%:!#?M+T6ZS=GS&XYG501^P^]1 /YF%["X1RYMD?O8 M)>)R[R_B$?Y$_VR53^;O'-Z*@A5Q*7?^I7UV.CF^TYJ?!_?UO]N]7+T_N5,N MU?'78;\^>?@VX.W&:>7FYO/YJ::T%;4XO<\Y9Q?Z-3VT>L.B>?G8/+J5[ZIO'"5#^Y_MJXO//H:?'[F5MM/%:^LHNKK[Q[ZO4_50=MNWSX M-.T,C7/KS-J^N3E^X->6.?#*7YY.FHUBM]T\G33/CV^>=NZNO?NS._?$KH_^ MMC[;5JEPR6^.C$^'G;.GL^NCT=67$\UX.-?O^7BD=XK3QMWPV]]W56:?]L_8 MW^7R?>N[=][\QA_SE;.)D[LYA8"UPT^42=7\7K1RXV_]P]SQY[OQP8&D2 [_ M@0#QKU"X(Z/V?U!+ 0(4 Q0 ( .N!S5J%(:P<,P, D, 1 M " 0 !R;F%Z+3(P,C4P-C$R+GAS9%!+ 0(4 Q0 ( .N!S5HD M+LV,_ H '^& 5 " 6(# !R;F%Z+3(P,C4P-C$R7VQA M8BYX;6Q02P$"% ,4 " #K@BTR,#(U,#8Q,E]P&UL4$L! A0#% @ ZX'-6F?F MO [$% 1F8 !( ( !)Q8 '1M,C4Q-SDY,&0Q7SAK+FAT 7;5!+!08 ! $ 4! ;*P ! end XML 14 tm2517990d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001829635 2025-06-12 2025-06-12 iso4217:USD shares iso4217:USD shares false 0001829635 8-K 2025-06-12 TRANSCODE THERAPEUTICS, INC. DE 001-40363 81-1065054 6 Liberty Square #2382 Boston MA 02109 857 837-3099 false false false false Common Stock, par value $0.0001 per share RNAZ NASDAQ true false